FavipiravirDisseminated erythematous drug eruption following an off-label use: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2023年 / 1982卷 / 1期

关键词：

D O I：

10.1007/s40278-023-49125-4

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：188 / 188

相关论文

共 50 条

[1] AnakinraFirst report of pruriginous erythematous pustules following an off-label use: case report
[J]. Reactions Weekly, 2016, 1603 (1) : 24 - 24
[2] AnakinraLarge erythematous reactions at the injection sites following off-label use: case report
[J]. Reactions Weekly, 2023, 1978 (1) : 38 - 38
[3] ErtapenemAcquired drug resistance following off-label use: case report
[J]. Reactions Weekly, 2022, 1909 (1) : 245 - 245
[4] Multiple drugsUrticaria following off-label use and drug eruption: 2 case reports
[J]. Reactions Weekly, 2020, 1823 (1) : 254 - 254
[5] HydroxychloroquineDrug eruption due to off-label use: case report
[J]. Reactions Weekly, 2022, 1932 (1) : 301 - 301
[6] RituximabPancytopenia following off-label use: case report
[J]. Reactions Weekly, 2020, 1807 (1) : 176 - 176
[7] FavipiravirNephrotoxicity following off-label use: case report
[J]. Reactions Weekly, 2022, 1929 (1) : 283 - 283
[8] DexamethasoneHyperglycaemia following off-label use: case report
[J]. Reactions Weekly, 2022, 1896 (1) : 173 - 173
[9] DexamfetamineHypertension following off-label use: case report
[J]. Reactions Weekly, 2021, 1883 (1) : 150 - 150
[10] NivolumabFever following off-label use: case report
[J]. Reactions Weekly, 2016, 1601 (1) : 186 - 186

← 1 2 3 4 5 →